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Abstract
Background: Adequate fluid management is an important component of patient care following cardiac surgery.
Our aim in this study was to determine the benefits of tolvaptan, an oral selective vasopressin-2 receptor antagonist
that causes electrolyte-free water diuresis, in postoperative fluid management. We prospectively examined the
effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in cardiac surgery patients.
Methods: Patients undergoing coronary artery bypass surgery were randomized to receive conventional loop
diuretics (Group C, n = 30) or conventional loop diuretic therapy plus tolvaptan (Group T, n = 27). Fractional
excretions of sodium (FENA), potassium (FEK) and urea nitrogen (FEUN) were measured in both groups during
post-surgical hospitalization.
Results: Urine output was greater with tolvaptan (Group T) than without it (Group C), and some patients in Group
C required intravenous as well as oral loop diuretics. Serum sodium concentrations decreased after surgery in
Group C, but were unchanged in Group T (postoperative day [POD] 3, 139.8 ± 3.5 vs. 142.3 ± 2.6 mEq/L, p = 0.006).
However, postoperative FENA values in Group C did not decrease, and the values were similar in both groups.
Serum potassium levels remained lower and FEK values remained higher than the preoperative values, but only in
Group C (all p < 0.05). BUN increased postoperatively in both groups, but it remained higher than its preoperative
value only in Group C (all p < 0.01). Group T showed an initial increase in BUN, which peaked and then returned to
its preoperative value within a week. The FEUN increased postoperatively in both groups, but the change was more
pronounced in Group T (POD7, 52.7 ± 9.3 vs. 58.2 ± 6.5 %, p = 0.025).
Conclusions: Renal excretion of sodium and potassium reflects the changes in serum concentration in patients
treated with tolvaptan. Patients treated only with loop diuretics showed a continuous excretion of sodium and
potassium that led to electrolyte imbalance, whereas the combination of loop diuretics and tolvaptan increased
renal urea nitrogen elimination. Tolvaptan therefore appears to be an effective diuretic that minimally affects serum
electrolytes while adequately promoting the elimination of urea nitrogen from the kidneys in patients undergoing
coronary artery bypass surgery.
Trial registration: The present study is registered with the UMIN Clinical Trials Registry (ID: UMIN000011039)
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Background
Fluid management following cardiac surgery is one of the
most important parts of postoperative cardiac patient care
[1, 2]. Loop diuretics are commonly administrated postop-
eratively; however, their continuous usage sometimes leads
to electrolyte imbalances, neurohumoral activation, wors-
ening renal failure, and diuretic resistance [3]. Loop di-
uretics inhibit sodium reabsorption at the thick ascending
limb of the loop of Henle and passively increase water ex-
cretion. Consequently, loop diuretics cause hyponatremia.
However, the efficacy of loop diuretics is reduced under
hyponatremia, resulting in a need to increase the dosage.
This, in turn, further worsens the hyponatremia, creating
a futile cycle [4]. In addition, loop diuretics increase so-
dium delivery to the distal segment of the distal tubule,
which stimulates the aldosterone-sensitive sodium pump
to increase sodium reabsorption in exchange for potas-
sium. Volume depletion causes further increases in aldos-
terone secretion, resulting in excessive urinary potassium
secretion and hypokalemia [3, 4]. Hypokalemia, in turn,
may provoke both supraventricular and ventricular post-
operative cardiac arrhythmias, with adverse effects on
myocardial contractility [5]. These adverse effects of loop
diuretics emphasize the need for better therapeutics for
postoperative fluid management in cardiac patients.
One promising candidate is tolvaptan, an oral selective
vasopressin V2-receptor antagonist that causes electrolyte-
free water diuresis [6, 7]. Water balance in the early
postoperative phase is modulated by the level of plasma
arginine vasopressin (AVP), which increases in response
to operative stress [8, 9]. AVP plays an important role in
water reabsorption at the renal collecting duct and this in-
crease causes an excessive body water imbalance during
the early postoperative phase. The use of a vasopressin in-
hibitor like tolvaptan, which promotes water excretion
without changes in renal hemodynamics or sodium and
potassium excretion [6], therefore may represent an ideal
strategy for maintaining fluid balance in patients undergo-
ing cardiac surgery. Furthermore, tolvaptan may have
benefits in reducing blood urea nitrogen (BUN) levels,
which are associated with increased cardiovascular
mortality and morbidity [10, 11]. Vasopressin promotes
reabsorption of urea in the distal nephron, resulting in
increased BUN [12]; therefore, vasopressin inhibition
by tolvaptan treatment may also be effective for eliminat-
ing the excessive BUN associated with surgery-induced
protein catabolism.
To the best of our knowledge, no detailed study has
yet examined the effect of tolvaptan on renal electrolyte
excretion following cardiac surgery. Therefore, we pro-
spectively compared the fractional excretion of electro-
lytes and urea nitrogen in postoperative cardiac surgery




Data on the effects of tolvaptan on changes in body weight
and other clinical parameters after bypass surgery were col-
lected at Juntendo University Hospital. Seventy patients
undergoing off-pump coronary artery bypass surgery were
prospectively enrolled in the study and randomized to ei-
ther the group receiving conventional loop diuretic treat-
ment only (Group C) or the group receiving conventional
loop diuretic treatment plus tolvaptan (Group T). Patients
in Group T received tolvaptan 7.5 mg once daily on post-
operative days 1 and 2, in addition to conventional oral
loop diuretics; intravenous loop diuretics were given only if
needed. Tolvaptan was administered as needed from post-
operative day 3 in Group T patients. Patients in Group C
received only conventional loop diuretic therapy. Patients
with renal insufficiency, such as those with chronic kidney
disease stage 4 or greater, were excluded from the study.
Patients requiring emergency surgery, those undergoing
cardiopulmonary bypass, and those undergoing concomi-
tant extracardiac/vascular and/or valvular surgery were
also excluded. Laboratory values were serially measured
after surgery for up to 7 days during hospitalization, and
the fractional excretion of sodium (FENA), potassium
(FEK), and urea nitrogen (FEUN) were calculated for both
groups of patients.
The study was approved by the institutional review
board of Juntendo University Hospital (UMIN000011039).
All participants received detailed information about the
study and provided written informed consent.
Statistical analysis
Data are presented as mean ± SD. Normality was evalu-
ated for each variable from normal distribution plots
and histograms. Data obtained at the same time-point
were compared between groups using Student’s unpaired
two-tailed t-test for continuous variables and the chi-
square test for categorical variables. Intragroup changes
in preoperative vs. postoperative values were assessed
with Student’s paired t-test. All data were analyzed using
the Statistical Analysis Systems software JMP 11.0 (SAS
Institute Inc., Cary, NC, USA).
Results
Patient characteristics
A total of 70 patients scheduled to undergo off-pump
coronary artery bypass surgery were initially reviewed.
Of those, 2 patients were excluded as they required an-
other procedure in addition to bypass surgery. After
randomization of patients into Groups T and C, incom-
plete datasets were collected from 7 patients in Group T
and 4 patients in Group C. Therefore, analyzable data
were obtained from 27 patients in Group T and 30 pa-
tients in Group C (Fig. 1).
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Patient demographics, laboratory values prior to the
surgery, and operative information for both groups are
summarized in Table 1. Age, gender distribution, body
surface area, and preoperative laboratory values, includ-
ing the estimated glomerular filtration rate (eGFR), did
not differ between the groups. The average operative
duration was around 240 min, and the mean number of
grafts was 3 in both groups.
Postoperative urinary output
Both groups received loop diuretics after surgery in a
routine manner in order to rectify postoperative hyper-
volemia. In our institution, Lasix® 40 mg per day orally is
generally given to patients undergoing coronary bypass
surgery. Additional Lasix® is administered intravenously
if a patient’s hourly urine output is approximately less
than 50 mL. In the present study, only some patients in
Group C required additional intravenous loop diuretics
(Fig. 2). Even so, the amounts of urine after surgery were
greater in Group T than in Group C, and the differences
were statistically significant on postoperative days 2 and
3. The estimated glomerular filtration rate (eGFR) values
were not significantly different between the groups
throughout the entire study period (Fig. 2).
Serial changes in serum electrolytes, FENA, and FEK
Figure 3 shows the serial changes in serum sodium con-
centrations and FENA before and after surgery in both
groups. We were unable to obtain values at postopera-
tive days 4 and 6 from some patients; therefore, the data
from postoperative days 4 and 6 were omitted from the
analysis. Serum sodium concentrations decreased postop-
eratively in Group C (from pre-surgery to postoperative
days 2, 5, and 7, p = 0.046, 0.027, and 0.029, respectively),
but they remained unchanged in Group T. Comparison of
the values between the groups revealed that postoperative
Fig. 1 Flow chart of patient classification. A total of 70 patients scheduled to undergo coronary artery bypass surgery met the study inclusion
criteria. Data for analysis were obtained from 30 patients treated with conventional diuretics only and from 27 patients treated with conventional
diuretics plus tolvaptan






Age (years) 69.0 ± 10.7 70.1 ± 7.5 0.697
Men 23 (85.2 %) 20 (66.7 %) 0.189
Body surface area (m2) 1.70 ± 0.16 1.60 ± 0.16 0.061
Preoperative laboratory examinations
Hb (g/dL) 11.9 ± 1.9 12.3 ± 1.2 0.341
Na (mEq/L) 141.5 ± 3.2 140.9 ± 3.1 0.537
K (mEq/L) 4.2 ± 0.2 4.3 ± 0.3 0.225
BUN (mg/dL) 14.3 ± 5.3 14.3 ± 5.5 0.965
Cre (mg/dL) 0.86 ± 0.32 0.80 ± 0.28 0.466
T-Bil (mg/dL) 1.0 ± 0.3 1.1 ± 0.2 0.065
TP (g/dL) 6.3 ± 0.5 6.3 ± 0.4 0.805
Alb (g/dL) 3.6 ± 0.3 3.4 ± 0.5 0.363
eGFR (ml/min./1.73 m2) 77.7 ± 31.0 76.4 ± 25.4 0.871
BNP (pg/mL) 263.1 ± 201.0 276.6 ± 197.5 0.814
Operative information
Operative duration (minutes) 247.7 ± 54.3 240.1 ± 64.3 0.688
Number of grafts 3.0 ± 1.1 2.9 ± 1.3 0.899
Abbreviations not defined in the text: Hb hemoglobin, Na sodium, K
potassium, Cre creatinine, T-Bil total bilirubin, TP total protein, Alb albumin,
BNP brain natriuretic peptide
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Fig. 2 Serial changes in the amounts of daily urinary output after surgery and eGFR (upper), and numbers of patients who required intravenous
loop diuretic administration (lower). Dark gray spotted bars and black circles indicate values for patients receiving conventional diuretic therapy
plus tolvaptan (Group T) and gray bars and white circles indicate values for patients receiving conventional diuretic therapy only (Group C). POD,
postoperative day
Fig. 3 Serial changes in sodium concentrations (upper) and FENA (lower) in patients receiving conventional diuretics plus tolvaptan (black symbols
and solid lines) or conventional diuretics only (white symbols and dotted lines). FENA, fractional excretion of sodium; POD, postoperative day
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serum sodium concentrations at postoperative days 2,
3, 5, and 7 were higher in Group T than in Group C.
However, even though the serum sodium concentrations
decreased postoperatively in Group C, the renal sodium
excretion in that group remained constant. In other words,
FENA did not decrease in Group C.
Figure 4 shows the serial changes in serum potassium
concentrations and FEK before and after surgery. Serum
potassium levels in both groups showed a gradual decrease
after surgery until postoperative day 3 (from pre-surgery to
postoperative day 3: for 4.2 ± 0.2 to 3.9 ± 0.2 mEq/L for
Group T and 4.3 ± 0.3 to 3.9 ± 0.3 mEq/L for Group C,
both p < 0.001). After postoperative day 3, serum potas-
sium levels in Group T returned to the preoperative range,
whereas the levels stayed lower in Group C. The FEK
values increased from their preoperative value on postop-
erative day 1 in both groups (both p < 0.001). In Group C,
the FEK values further increased until postoperative day 3,
and they remained higher than the preoperative value
(from pre-surgery to postoperative days 2, 3, and 5, all
p < 0.001). In Group T, the FEK value, which was higher
on postoperative day 1 than on the preoperative value,
decreased and returned to the preoperative range after
postoperative day 2.
Serial changes in blood urea nitrogen (BUN) and FEUN
Figure 5 shows the serial changes in BUN levels and FEUN
before and after surgery. BUN increased postoperatively in
both groups, but remained higher than its preoperative
value until postoperative day 7 in Group C (from pre-
surgery to postoperative day 7, 14.3 ± 5.5 to 21.0 ± 9.9 mg/
dL, p = 0.0003). In Group T, the increase in BUN peaked
on postoperative day 2 and then gradually decreased to its
preoperative value.
In both groups, FEUN increased postoperatively and
remained higher than the preoperative values. The in-
crease in postoperative FEUN was more pronounced
in Group T. Intergroup comparison showed that the
FEUN values at postoperative days 2 and 7 were statistically
higher in Group T than in Group C (p = 0.049 and 0.025,
respectively).
Postoperative clinical courses
The postoperative clinical courses in all patients are
compared in Table 2. Because some patients were seen
at outside community hospitals after discharge, we were
unable to gather long-term data, such as laboratory ex-
aminations, from all patients. No differences were evi-
dent in mortality between the groups up to 2.9 years
after the surgery (mean 2.1 years). The occurrence of
perioperative adverse events was not statistically differ-
ent between the groups. None of the patients required
renal replacement therapy after the surgery; however,
one patient in Group T (3.7 %) and 4 in Group C (13 %)
developed RIFLE classification-R (risk) acute kidney in-
jury (AKI) [13].
Fig. 4 Serial changes in potassium concentrations (upper) and FEK (lower) in patients receiving conventional diuretics plus tolvaptan (black symbols
and solid lines) or conventional diuretics only (white symbols and dotted lines). FEK, fractional excretion of potassium; POD, postoperative day
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Discussion
In the present investigation, both groups of patients re-
ceived loop diuretics after surgery; therefore, the data
did not reflect any independent effect of tolvaptan on
renal excretion of electrolytes and urea nitrogen, as
these were also influenced by the conventional loop di-
uretics. Even so, we believe that our detailed observa-
tions of the serial daily changes in laboratory values in
serum and urine can aid in understanding how tolvaptan
affects renal excretion mechanisms in patients undergo-
ing cardiac surgery.
Our data show that (i) the amount of daily urine output
was well maintained and somewhat greater with tolvaptan
(Group T) than without it (Group C), although some pa-
tients in Group C required intravenous loop diuretic ad-
ministration; (ii) serum sodium concentrations decreased
after surgery only in Group C, but the postoperative FENA
values were not significantly different with or without tol-
vaptan; (iii) in the absence of tolvaptan (Group C), postop-
erative serum potassium concentrations decreased and
stayed lower than the preoperative level, with an associated
increase in FEK. By contrast, the addition of tolvaptan
(Group T) maintained the postoperative serum potassium
levels at essentially the preoperative levels; and (iv) both
groups showed an increase in BUN and FEUN after sur-
gery, but tolvaptan treatment led to a higher FEUN and a
rapid decrease in BUN as time progressed.
We speculate that the similar FENA values with and
without tolvaptan after surgery may reflect an enhance-
ment of the effectiveness of loop diuretics by tolvaptan.
Previous papers have also noted that concomitant ad-
ministration of tolvaptan enhances the effects of loop di-
uretics [14]. Nishizaki et al. showed an enhancement of
natriuresis that could be an indirect effect of tolvaptan,
and they assumed that tolvaptan relieves renal conges-
tion, thereby enhancing the performance of the loop
diuretics [14]. Furthermore, the dose-response curves
for the loop diuretics [15] indicate that patients with
renal insufficiency and/or heart failure require a higher
Fig. 5 Serial changes in BUN levels (upper) and FEUN (lower) in patients receiving conventional diuretics plus tolvaptan (black symbols and solid lines)
or conventional diuretics only (white symbols and dotted lines). FEUN, fractional excretion of urea nitrogen; POD, postoperative day






Mortality, n (%)a 0 (0 %) 0 (0 %) -
Duration of intensive care unit
stay (days)
1.3 ± 1.9 1.2 ± 1.3 0.816
Bleeding amount (mL) 324.2 ± 273.4 308.4 ± 202.3 0.804
Intubation time (hours) 9.3 ± 5.3 11.2 ± 6.4 0.230
Perioperative adverse events, n (%)
Neurological complications, n (%) 0 (0 %) 0 (0 %) -
Arrhythmia, n (%) 6 (22.2 %) 8 (26.7 %) 0.697
Renal replacement therapy, n (%) 0 (0 %) 0 (0 %) -
RIFLE classification-Risk, n (%) 1 (3.7 %) 4 (13.3 %) 0.467
aThe observation period for mortality was 2.9 years (mean 2.1 years)
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diuretic dose to achieve the desired FENA. Therefore,
our finding that the patients in Group T showed a simi-
lar FENA value to patients in Group C under a smaller
loop diuretic dosage could be confirmation that tolvap-
tan enhances loop diuretic-induced natriuresis.
In the current study, both groups of patients were
placed on a salt-restricted diet soon after surgery, and
the amount of peroral sodium intake did not likely differ
between the groups. Therefore, the higher serum sodium
concentration seen in Group T, compared to Group C,
might have resulted from the effective free-water diuresis
induced by tolvaptan in Group T. Indeed, the amount of
daily urine volume was larger in Group T soon after sur-
gery (Fig. 2). In addition, the serum albumin levels were
substantially higher in Group T than Group C after surgery
(e.g., postoperative day 5, 3.3 ± 0.3 vs. 3.5 ± 0.2 mg/dL,
p = 0.024). Probably because the number of studied
patients was too small, we failed to show a tolvaptan
effect on eGFR values (Fig. 2); however, there was a
tendency for the patients in Group C to develop RI-
FLE classification-R (risk) AKI more frequently than
the patients in Group T. This result may reflect the
findings by Shirakabe et al., who reported that early
administration of tolvaptan could prevent exacerba-
tion of AKI in heart failure patients [16].
The decrease in serum potassium concentrations and
the slight increase in FEK after surgery in Group C are
reasonable responses to loop diuretic therapy. Group T
patients also received loop diuretics, although the dosage
was smaller than in Group C, and the changes in their
serum potassium and FEK values soon after surgery
showed similar trends to those in Group C.
The increase in BUN just after surgery most likely re-
flects surgery-induced protein catabolism. Although the
operative duration was about 4 h and the peri-operative
fasting period was approximately 1 day in both groups,
maintenance fluid replacement, together with the fast-
ing, would elicit protein degradation. However, the sus-
tainment of this increase in BUN after surgery may also
reflect neurohormonal activation and renal hypoperfu-
sion [10, 11, 17, 18]. Testani et al. reported that exces-
sive neurohormonal activation, as estimated by BUN
elevation, can predict potential adverse effects of loop
diuretics [19]. Several studies have suggested that BUN
is a simple and significant prognostic marker associated
with morbidity and mortality in patients with heart failure
[10, 11, 17, 18, 20], and increases in BUN appear to be as-
sociated with cardiovascular mortality [11, 20]. In patients
with heart failure, an increase in renin-angiotensin aldos-
terone system activity provokes urea reabsorption at
the proximal tubule, while sympathetic nervous system
activation promotes urea reabsorption at the distal and
proximal tubules, and elevation of AVP upregulates
urea transporters in the collecting tubule [12, 18]. Our
observations indicate that tolvaptan could reasonably
modulate this AVP-associated urea reabsorption, as indi-
cated by the decrease in BUN in Group T.
Operative stress induces neurohormonal activation
and increases serum AVP levels [8, 9]. The measure-
ments of serum AVP levels in 239 critically ill patients
and 70 healthy volunteers by Jochberger et al. confirmed
higher AVP concentrations in patients undergoing cardiac
surgery than in patients undergoing noncardiac surgery or
who had nonsurgical diseases [21]. Terazawa et al. re-
ported that serum AVP levels increased during and soon
after cardiac surgery, and that the increase was larger in
patients with more severe conditions [22]. Therefore,
patients undergoing cardiac surgery could have a volume
overload that could be related to increased plasma AVP
due to operative stress. We believe that tolvaptan may be
an ideal diuretic for neurohormonal control as well as
maintenance of adequate electrolyte balance. Furthermore,
tolvaptan may cause excretion of the excessive BUN pro-
duced by protein catabolism and operative stress, which
may be beneficial for long-term prognoses.
We admit that tolvaptan is a relatively expensive medi-
cation; however, it effectively enables diuresis without
causing electrolyte imbalance, which is helpful in the
management of postsurgical patients who are at high
risk for cardiac arrhythmia and for progression to acute
kidney injury. Therefore, the high cost of this treatment
may be offset by reductions in the lengths of stays in the
intensive care unit and further costly postsurgical treat-
ment. Additional studies are needed to analyze the effi-
cacy of tolvaptan on a medical-care cost basis in patients
undergoing cardiac surgery. Moreover, elevated BUN
and low sodium concentration have well known associa-
tions with poor patient prognosis [10, 11, 16], and tolvap-
tan treatment is expected to improve survival in heart
failure patients by normalization of these factors [23]. The
present observation that urea nitrogen excretion was en-
hanced by tolvaptan treatment without affecting sodium
concentration supports this expectation. The effect of
tolvaptan on long-term prognosis in patients undergoing
cardiac surgery should be further investigated.
The present study had several limitations. First, this
was a single-center, retrospective, observational analysis
with a small number of patients. According to the proto-
col, tolvaptan was given only on postoperative days 1
and 2 in Group T, and the decision to continue tolvap-
tan was up to the attending doctor. Therefore, among
the Group T patients, some received tolvaptan through-
out their hospital stay and some received it for only
2 days. This may have affected the data obtained after
postoperative day 3, which complicates the interpret-
ation of our results. In addition, because most of the
patients were able to consume fluids orally within a day
after surgery, we were unable to estimate the effect of
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intravenous fluid administration on serum and/or urin-
ary electrolytes. We also did not measure plasma AVP
levels or urine Aquaporin-2, which have been reported
to be predictive markers of the response to tolvaptan
[24, 25]. Other than diuretics, we did not include infor-
mation on the use of other drugs, such as inotropic
agents and beta-blockers. Furthermore, we reviewed
only the short-term clinical course and did not review
long-term outcomes. Lastly, the objective variables had
a relatively larger standard deviation than we initially
expected, so the statistical power derived from the
present results was not sufficient to draw conclusions.
However, this is a preliminary analysis and we would
like to enroll greater numbers of patients in more spe-
cific studies.
Conclusions
In conclusion, loop diuretics can cause continuous ex-
cretion of sodium and potassium, irrespective of their
serum concentrations, which may result in electrolyte
imbalance. The addition of tolvaptan in the present
study prevented the generation of an electrolyte imbal-
ance in the cardiac surgery patients investigated here.
Furthermore, tolvaptan seems to enhance the effective-
ness of loop diuretics. Tolvaptan also showed potential
to promote the excretion of urea nitrogen produced by
protein catabolism and in response to operative stress,
and it does so more effectively than loop diuretics in pa-
tients undergoing coronary artery bypass surgery.
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